AML1-ETO Inhibits Maturation of Multiple Lymphohematopoietic Lineages and Induces Myeloblast Transformation in Synergy with ICSBP Deficiency
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
The translocation (8;21), generating the AML1-ETO fusion protein, is one of the most frequent chromosomal abnormalities associated with acute myelogenous leukemia (AML). To elucidate its role in oncogenesis, bone marrow (BM) cells were infected with a retroviral vector carrying AML1-ETO and transplanted into mice. In contrast to previous transgenic mouse models, we show that AML1-ETO directly stimulates granulopoiesis, suppresses erythropoiesis, and impairs the maturation of myeloid, B, and T lymphoid cells in vivo. To determine the significance of earlier findings that expression of the tumor suppressor ICSBP is often downregulated in AML myeloblasts, AML1-ETO was introduced into BM cells derived from mice lacking the interferon regulatory factor ICSBP. Our findings demonstrate that AML1-ETO synergizes with an ICSBP deficiency to induce myeloblastic transformation in the BM, reminiscent of AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856
Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages
Scott, E. W., Simon, M. C., Anastasi, J., & Singh, H. (1994) · Science · doi:10.1126/science.8079170 · Cited by 1,532
Wang, Q., Stacy, T., Binder, M., Marin-Padilla, M., Sharpe, A. H., & Speck, N. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3444 · Cited by 1,178
Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities
McKercher, S. R., Torbett, B. E., Anderson, K. L., Henkel, G. W., Vestal, D. J., Baribault, H., Klemsz, M., Feeney, A. J., Wu, G. E., Paige, C. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00949.x · Cited by 1,130
Zhang, D.-E., Zhang, P., Wang, N.-D., Hetherington, C. J., Darlington, G. J., & Tenen, D. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.569 · Cited by 910
Miyoshi, H., Shimizu, K., Kozu, T., Maseki, N., Kaneko, Y., & Ohki, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10431 · Cited by 872
Transcription Factors, Normal Myeloid Development, and Leukemia
Tenen, D. G., Hromas, R., Licht, J. D., & Zhang, D.-E. (1997) · Blood · doi:10.1182/blood.v90.2.489 · Cited by 735 · cited 14×
“1228 AML1-ETO Inhibits Maturation of Multiple Lymphohematopoietic Lineages ing to the repression of genes containing CBF-binding sites in their promoter/enhancer region (12, 15, 16).”
BackgroundInfluentialHoltschke, T., Löhler, J., Kanno, Y., Fehr, T., Giese, N., Rosenbauer, F., Lou, J., Knobeloch, K.-P., Gabriele, L., Waring, J. F., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81348-3 · Cited by 644 · cited 6×
“It has recently been proposed that ICSBP expression is downregulated by the CML oncogene BCR-ABL, thus it will be of interest to determine if ICSBP expression is a downstream target of other tyrosine kinases, e.g., Flt3 and c-kit, which have been found to be mutated in patients with t(8;21) AML (74, 75).”
BackgroundResultInfluentialSelf-citationErickson, P., Gao, J., Chang, K., Look, T., Whisenant, E., Raimondi, S., Lasher, R., Trujillo, J., Rowley, J., & Drabkin, H. (1992) · Blood · doi:10.1182/blood.v80.7.1825.1825 · Cited by 631
The CBFβ Subunit Is Essential for CBFα2 (AML1) Function In Vivo
Wang, Q., Stacy, T., Miller, J. D., Lewis, A. F., Gu, T.-L., Huang, X., Bushweller, J. H., Bories, J.-C., Alt, F. W., Ryan, G., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81389-6 · Cited by 621
Ogawa, E., Maruyama, M., Kagoshima, H., Inuzuka, M., Lu, J., Satake, M., Shigesada, K., & Ito, Y. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6859 · Cited by 608
Miyoshi, H., Kozu, T., Shimizu, K., Enomoto, K., Maseki, N., Kaneko, Y., Kamada, N., & Ohki, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05933.x · Cited by 498
Miyamoto, T., Weissman, I. L., & Akashi, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.13.7521 · Cited by 465 · cited 2×
“In contrast, by introducing AML1-ETO by retroviral transduction into murine adult HSC, the origin of t(8;21) (33) and the target cell of AML transformation (32, 34), we could demonstrate that normal hematopoiesis is disrupted at several levels by AML1-ETO expression in vivo.”
BackgroundAML1–ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia
Pabst, T., Mueller, B. U., Harakawa, N., Schoch, C., Haferlach, T., Behre, G., Hiddemann, W., Zhang, D.-E., & Tenen, D. G. (2001) · Nature Medicine · doi:10.1038/86515 · Cited by 463 · cited 10×
“Significantly, granulocytic sarcomas are observed at a relatively high incidence in t(8;21) AML (54, 55), and can be the first manifestation of AML (56, 57).”
BackgroundResultInfluentialZhang, D.-E., Hetherington, C. J., Meyers, S., Rhoades, K. L., Larson, C. J., Chen, H.-M., Hiebert, S. W., & Tenen, D. G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.3.1231 · Cited by 396
The t(8;21) Fusion Protein Interferes with AML-1B-Dependent Transcriptional Activation
Meyers, S., Lenny, N., & Hiebert, S. W. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.4.1974 · Cited by 368 · cited 1×
“1228 AML1-ETO Inhibits Maturation of Multiple Lymphohematopoietic Lineages ing to the repression of genes containing CBF-binding sites in their promoter/enhancer region (12, 15, 16).”
BackgroundYergeau, D. A., Hetherington, C. J., Wang, Q., Zhang, P., Sharpe, A. H., Binder, M., Marín-Padilla, M., Tenen, D. G., Speck, N. A., & Zhang, D.-E. (1997) · Nature Genetics · doi:10.1038/ng0397-303 · Cited by 346
Asou, H., Tashiro, S., Hamamoto, K., Otsuji, A., Kita, K., & Kamada, N. (1991) · Blood · doi:10.1182/blood.v77.9.2031.2031 · Cited by 291
Westendorf, J. J., Yamamoto, C. M., Lenny, N., Downing, J. R., Selsted, M. E., & Hiebert, S. W. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.322 · Cited by 270 · cited 3×
“Although several myeloid genes are regulated by CBF (6, 7), accumulating evidence suggest that AML1-ETO may exert its effect by protein interaction with other transcription factors, such as PU.1 and C/EBP (18, 19, 64), both of which play a pivotal role in myeloid differentiation, as demonstrated in knock-out mice (66–…”
BackgroundMultiple Functional Domains of AML1: PU.1 and C/EBPα Synergize with Different Regions of AML1
Petrovick, M. S., Hiebert, S. W., Friedman, A. D., Hetherington, C. J., Tenen, D. G., & Zhang, D.-E. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3915 · Cited by 218 · cited 3×
“Although several myeloid genes are regulated by CBF (6, 7), accumulating evidence suggest that AML1-ETO may exert its effect by protein interaction with other transcription factors, such as PU.1 and C/EBP (18, 19, 64), both of which play a pivotal role in myeloid differentiation, as demonstrated in knock-out mice (66–…”
BackgroundThe AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells
Mulloy, J. C., Cammenga, J., MacKenzie, K. L., Berguido, F. J., Moore, M. A. S., & Nimer, S. D. (2002) · Blood · doi:10.1182/blood.v99.1.15 · Cited by 208 · cited 1×
“Importantly, a recent study in which human CD34 enriched cells were transduced with a retroviral vector expressing AML1-ETO also noted a pronounced bias toward immature myeloid cells after in vitro culture (65).”
BackgroundLack of Interferon Consensus Sequence Binding Protein (ICSBP) Transcripts in Human Myeloid Leukemias
Schmidt, M., Nagel, S., Proba, J., Thiede, C., Ritter, M., Waring, J. F., Rosenbauer, F., Huhn, D., Wittig, B., Horak, I., et al. (1998) · Blood · doi:10.1182/blood.v91.1.22 · Cited by 199
Self-citationHao, S. X., & Ren, R. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.4.1149-1161.2000 · Cited by 143
Regulation of Apoptosis in Myeloid Cells by Interferon Consensus Sequence–Binding Protein
Gabriele, L., Phung, J., Fukumoto, J., Segal, D., Wang, I.-M., Giannakakou, P., Giese, N. A., Ozato, K., & Morse, H. C. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.411 · Cited by 114 · cited 1×
“The ICSBP deficiency results in an expansion of the early myeloid progenitor pool, probably due to an increased sensitivity to proliferation stimuli and a decreased response to apoptotic stimuli (38, 39).”
BackgroundMeyers, S., Downing, J. R., & Hiebert, S. W. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.10.6336-6345.1993 · Cited by 94 · cited 1×
“The Runt homology domain (RHD) (8) at the amino terminus of AML1 is included in the fusion protein and has been shown to be required for heterodimerization with CBF and for DNA binding (9).”
BackgroundSchmidt, M., Hochhaus, A., Nitsche, A., Hehlmann, R., & Neubauer, A. (2001) · Blood · doi:10.1182/blood.v97.11.3648 · Cited by 77 · cited 1×
“The relevance of this observation in human leukemia was confirmed by the demonstration that ICSBP is downregulated in 79 and 66% of patients with CML and AML, respectively (40, 41).”
Background
Cited by
Transcription factors in myeloid development: balancing differentiation with transformation
Rosenbauer, F., & Tenen, D. G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2024 · Cited by 606
The runx genes: gain or loss of function in cancer
Blyth, K., Cameron, E. R., & Neil, J. C. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1607 · Cited by 455
A Multicolor Panel of Novel Lentiviral “Gene Ontology” (LeGO) Vectors for Functional Gene Analysis
Weber, K., Bartsch, U., Stocking, C., & Fehse, B. (2008) · Molecular Therapy · doi:10.1038/mt.2008.6 · Cited by 351
Self-citationThe 8;21 translocation in leukemogenesis
Peterson, L. F., & Zhang, D.-E. (2004) · Oncogene · doi:10.1038/sj.onc.1207727 · Cited by 302
Yan, M., Kanbe, E., Peterson, L. F., Boyapati, A., Miao, Y., Wang, Y., Chen, I.-M., Chen, Z., Rowley, J. D., Willman, C. L., et al. (2006) · Nature Medicine · doi:10.1038/nm1443 · Cited by 279
Metadata
- Authors
- Schwieger, M., Löhler, J., Friel, J., Scheller, M., Horak, I., & Stocking, C.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2002-11-04
- Volume
- 196
- Issue
- 9
- Pages
- 1227-1240
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2107367651
- Cited by
- 143
- References
- 26
- FWCI
- 5.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.